What is Mabwell?
Mabwell operates as a values-based, R&D-driven biopharmaceutical enterprise dedicated to addressing unmet medical needs in immunology, oncology, metabolic diseases, ophthalmology, and infectious diseases. The company distinguishes itself through a sophisticated, state-of-the-art R&D engine that integrates high-throughput screening for hybridoma antibodies, advanced B cell screening, and specialized platforms for ADC drug development and bispecific antibody engineering. With a comprehensive team spanning the entire drug lifecycle—from initial discovery and development to manufacturing and commercialization—Mabwell maintains a vertically integrated approach to pharmaceutical innovation. This operational structure allows the company to maintain rigorous quality standards while accelerating the path from molecular discovery to clinical application.
How much funding has Mabwell raised?
Mabwell has raised a total of $825.9M across 2 funding rounds:
Series A
$278M
Stock Offering
$547.9M
Series A (2020): $278M with participation from Oriental Fortune Capital, Shenzhen Shiyu Investment Management, Haitong Capital, and Loyal Valley Capital
Stock Issuance/Offering (2022): $547.9M, investors not publicly disclosed
Key Investors in Mabwell
Oriental Fortune Capital
A prominent venture capital firm focusing on high-growth sectors including healthcare, technology, and advanced manufacturing.
Loyal Valley Capital
An investment firm specializing in long-term value creation through strategic partnerships with industry-leading companies in the Chinese market.
Haitong Capital
The private equity and venture capital arm of Haitong Securities, providing comprehensive financial support to innovative enterprises.
What's next for Mabwell?
With the recent influx of capital, Mabwell is strategically positioned to accelerate its clinical development programs and expand its commercial footprint. The focus will likely shift toward the late-stage validation of its existing biologics pipeline and the potential scaling of its manufacturing infrastructure to meet global demand. As the company navigates the complexities of the biopharmaceutical market, the continued refinement of its PEGylation and bispecific antibody platforms will be essential for maintaining a competitive edge. Future strategic efforts will likely prioritize the optimization of its commercialization channels, ensuring that its innovative therapeutic portfolio reaches target patient populations efficiently while sustaining long-term value for its stakeholders.
See full Mabwell company page
